DaVita Inc. fell sharply to $163.64 on November 18, a 5.4% one‑day drop that left the stock well below its 40‑week average and deep in a downtrend. The balance of evidence remains strongly negative for the next two to six weeks, with the daily trend aligned to the weekly decline, a lag of –5.9% versus the S&P 500 over 50 days, and a –13.3% lag versus the healthcare sector XLV. The bearish stance, unchanged since the November 3 note, is supported by a high conviction rating.
Why it matters
The recent legal actions against DaVita – a Washington antitrust lawsuit accusing the company of suppressing competition and a Pomerantz LLP investigation into possible securities fraud – added fresh pressure to a stock already under stress from a proposed federal kidney‑care plan that could increase competition and regulatory oversight. The market reacted by pushing the price below the swing‑zone resistance at $171.21, a level where sellers have historically stepped in on rallies.
Much of the move was not simply a sector‑wide sell‑off. Over the past five days the stock fell –10.8%, while the broader market (SPY) dropped –4.1% and the healthcare sector XLV slipped –3.5%. The stock’s underperformance versus both the market (–5.9% over 50 days) and its sector (–13.3% over 50 days) shows that the decline is driven more by company‑specific risk than by a general market pullback.
Analysts remain cautiously optimistic on valuation, with a consensus “buy” rating and a mean price target of $222.3, but the current price is 26.4% below that target. The low‑end target of $165 is only marginally above today’s price, indicating that even the most conservative upside is limited given the present structure.
Debate in the market reflects two sides. A Yahoo! Finance piece from November 3 listed DaVita among “Warren Buffett stocks with upside potential,” citing the analyst consensus and target range as a bullish argument. Conversely, the legal filings and the recent earnings transcript, which highlighted a missed treatment rate and volume shortfall, provide a bearish counterpoint. Both perspectives are grounded in the same data set, but the weight of recent legal risk and price action tilts the balance toward the downside.
What the evidence says
The long‑term thesis that DaVita is in a downtrend remains intact. The price sits below both the 50‑day SMA ($181.93) and the 200‑day SMA ($181.69), and the 14‑day RSI at 34.2 signals oversold conditions but does not change the structural bias. The weekly trend is down, and the swing‑zone resistance at $171.21 continues to hold, confirming that the longer‑term bearish framework is still valid.
For the next two to six weeks the evidence leans strongly negative. The assessment calls for a bearish stance with high conviction, based on three of four conviction points: the daily trend follows the weekly downtrend, the stock lags the S&P 500 by –5.9% over 50 days, and it lags XLV by –13.3% over the same period. The breakout math requires a daily close below $156.84 to trigger the downside scenario, with a stop at $173.20 and targets at $146.70 and $143.92. The reward‑to‑risk ratios of 0.6 and 0.8 fall short of the preferred 3‑to‑1, indicating limited upside to the downside risk.
The strongest case against this reading would be a rapid rebound above the swing‑zone resistance at $171.21, coupled with a weekly close above $191.39, which would invalidate the current bearish picture. However, such a move would require a swing of more than 10% in a single week, a scenario not supported by the recent volatility profile – a one‑day drop of over 5% historically leads to a median one‑month gain of only 5.4%.
Levels that matter
The structure holds below the swing‑zone resistance at $171.21, a level where sellers have repeatedly emerged on attempts to rally. The weekly trend would be considered ended only if price closes above the 200‑day SMA at $181.69, a level that also marks the next resistance tier.
The breakout level for a downside move is a daily close below $156.84. If that occurs, the math projects targets at $146.70 and $143.92, with a stop set at $173.20 – a quarter of the 14‑day ATR ($7.95) added to the swing‑zone support at $171.21. Because the reward‑to‑risk does not reach 3‑to‑1, a price move to roughly $138 would be needed to achieve that ratio, which is well below the current support zone.
What would change the picture
A weekly close above the 200‑day SMA at $181.69 would alter the narrative, indicating that the weekly downtrend has been broken. Additionally, any resolution or dismissal of the antitrust lawsuit or the securities‑fraud investigation would remove a key catalyst for downside pressure.
What to watch
- Next earnings release on October 29, 2026 – focus on treatment rates and volume guidance.
- Sector developments, especially any regulatory changes to the kidney‑care market that could affect DaVita’s competitive position.
- Analyst price targets: mean $222.3 versus current price, with the low target of $165 providing a near‑term ceiling.